 |
BioWorld-International-2010-07-28
Global Group Maps Interface with Genome, Cancer Drugs
Cerenis' Series C Adds €40M for HDL Mimetic in CV Disease
Five-year-old French biotech Cerenis Therapeutics SA pulled in its third major venture round, adding €40 million (US$51.9 million) in Series C funding to advance its lead program, HDL-mimetic CER-001, into Phase II testing in cardiovascular disease. (BioWorld International)